NEW YORK (GenomeWeb News) — Nanogen has licensed genetic markers related to schizophrenia and to antipsychotic drug response from Australia’s Co-Operative Research Centre for Diagnostics and Queensland University of Technology.
 
Nanogen said it will use the markers to develop diagnostics for schizophrenia and “related conditions,” and said that some of the markers may be useful in predicting adverse drug reactions. The company said these markers have been linked to the disease “in a number of clinical studies.”
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.